Trans-institutional team documents potential new treatment path for breast cancerJan. 16, 2019, 9:16 AM
Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.
A Vanderbilt team led by John Wilson, assistant professor of chemical and biomolecular engineering, and Rebecca Cook, associate professor of cell and developmental biology, activated innate immunity in breast cancer cells and triggered two forms of tumor cell death in mouse models.